Get MindMed Updates:
We are researching & developing a broad range of compounds, with the goal of unlocking new pathways for patients to experience sustained mental healing.
We believe patients deserve better than to linger in symptom management forever. We help patients make breakthroughs that get them out of the symptom management cycle that’s all too commonplace in mental healthcare.
Effective mental healthcare requires a coordinated effort from therapists, drug developers, and patients. We need shared data to drive insights and better treatment, so we’re working to build that community through partnerships and programs. We hold ourselves and our partners to the highest standards of efficacy and compassion so that we can progress the industry — and patient outcomes — faster.
We’re not just another pill to manage symptoms. We offer a toolset — from breakthrough medicines and technology to compassionate therapy— for patients and therapists that accounts for the entire, complex patient journey.
Experiential therapies have a high enough dose of a psychedelic (e.g., LSD, psilocybin) to produce a hallucinogenic effect and are administered under the supervision and guidance of a medical professional.
Psychedelic Inspired Medicines are derived from psychedelics, yet have a zero to negligible hallucinogenic effect and can be prescribed by doctors and picked up at the pharmacy for at-home use.
Developing best-in-class mental health care means more than clinical testing. In addition to conducting trials for the compounds we’re bringing to market, we’re also focused on next-gen research & development, comprehensive treatment programs and integrated toolsets that empower therapists to focus on what they do best.
Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.
Co-Founder, Board Director & Co-CEO
Stephen L. Hurst, JD
Co-Founder, Executive Chair of the Board & Co-CEO
Dr. Miri Halperin Wernli
President; Board Director; Chair of Technology Evaluation, Acquisition and Scientific Integrity Board Committee
Chief Operating Officer
Donald Gehlert, PhD
Chief Scientific Officer
Chief Financial Officer
EVP, Technical Operations
Shahera St. John
Senior Director, Business Operations and Development
Senior Director Clinical Operations & Program Leader LSD
Director of Operations & Administration
Head of Corporate Development
Director, Business Process
Stanley D. Glick, PhD, MD
Board Director and Chair Scientific Advisory Board
Natalie Wheeler, PhD
Medical Science Liaison with Dova Pharmaceuticals
Matthew W. Johnson, Ph.D
Kenneth Alper, MD
Clinical Associate Professor of Psychiatry and Neurology at the New York University School of Medicine
Dr. Peter Gasser
Professor Dr. Matthias Liechti, PhD & M.D.
Scientific Collaborator & Advisor
Dr. Kim Kuypers
Scientific Collaborator & Advisor
Sarah McCallum, PhD
Associate Professor of Neuroscience and Experimental Therapeutics (DNET) at Albany Medical College
John Rotrosen, MD
Professor of Psychiatry with New York University’s Langone’s Department of Psychiatry
Board Director, Chair of Audit Commitee, Member of Compensation, Nomination and Governance Committee
Board Director, Member of Audit and Compensation, Nomination and Governance Committees
Board Director, Chair of Compensation, Nomination and Governance Committee, Member of Audit Committee
Scott Freeman, MD
Co-Founder & Clinical Advisor
Here to Stay
This is a rapidly evolving space; we’re committed to building a business that becomes a long-lasting institution in effective mental health treatment — not a flash-in-the-pan startup that’s here today and gone tomorrow.
We believe that, as a society, we’re at the start of a paradigm shift in mental health. We want to lead the way in doing it right. That means we’re community-focused, honest, and transparent. Together we can improve our collective mental health.
This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”
MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”
MindMed named one of 36 startups that could change the world